*NEW*Answer for your chance to receive a FREE RxTimes travel coffee mug!

What is the patient and the date that the first insulin injection was given?
Send your answer to stephen.grosch@rxtimes.com for a chance to be selected to receive a free RxTimes Magazine travel coffee mug!
Only confirmed subscribers are eligible. Please subscribe to RxTimes Magazine before submitting your answer.

Despite Concern, Americans Aren’t Protecting Themselves Against Diabetes

COLUMBUS, Ohio, April 28, 2010 - Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention (CDC). However, while nearly 60 percent of Americans are concerned about developing diabetes, many aren’t taking the necessary steps to protect their [...]

CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin™

EXETER, N.H.–(BUSINESS WIRE)–CPEX Pharmaceuticals Inc. (NASDAQ: CPEX) today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company’s nasal insulin product, Nasulin™. The study was designed to evaluate the efficacy and safety of Nasulin versus placebo over a 6-week treatment period in subjects with Type 2 diabetes who were being treated with [...]

U.S. Food And Drug Administration Accepts New Drug Application For Once-Daily Fixed Dose Combination Of Onglyza™ (Saxagliptin) And Extended Release Metformin For The Treatment Of Type 2 Diabetes Mellitus In Adults

PRINCETON, N.J. & WILMINGTON, Del. – Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a [...]

NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance

Basel, March 14, 2010 – Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.
Primary data from the NAVIGATOR (Nateglinide And Valsartan in Impaired [...]

4 Ways Pharmacists Will Make A BIG Impact In 2010

Medication therapy management (MTM) is becoming more and more important as many patients continue to participate in increasingly complex and difficult pharmacotherapeutic treatment regimens concurrently that target a variety of disease states. Pharmacists are experts at fine tuning treatment regimens to be effective and safe, sharing their expert advice with other healthcare professionals in order improve treatment outcomes and avoiding unnecessary healthcare cost. After years of observation, this concept has shown itself as quite valuable in the arena of healthcare. A study published by Barnett MJ, Frank J, Wehring H, et al. J Manag Care Pharm. 2009;15:18-31 found that “for every $8.44 reimbursed to community pharmacists for providing MTM, the average estimated cost avoided by the healthcare system was $93.78.” As time goes on pharmacists will be utilized more and more to become involved in MTM services as reimbursement has shown as a good investment in quality and cost efficient healthcare.